Are There Changes Ahead for the Generalized Anxiety Disorder Market?

Introduction

Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the major pharmaceutical markets, and drug therapy is considered the most effective treatment. The therapy market for GAD is crowded and includes many generic players, creating a diffi cult environment for launching new agents. Nonetheless, several emerging agents are set to challenge current market leaders.

Get the Answers You Need to Shape Your Strategy

• GAD can be very debilitating, causing those affected to significantly limit their activities. How many people in the major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) have GAD? What brain structures and neurotransmitters have been implicated in its development? How is the disease diagnosed?
• A variety of drug classes are used to treat GAD. What are the most popular therapies for GAD? What are their benefi ts and drawbacks?
• Several new agents for GAD should launch in the next few years. What agents are in the pipeline for GAD, and are they likely to replace any existing agents? What changes can be expected in the GAD market over the next five years?

Scope

• Overview of GAD: disease description, diagnosis, and pathophysiology.
• Epidemiology: total prevalent cases, diagnosed and drug-treated populations.
• Current therapies: selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and benzodiazepines.
• Emerging therapies: Sanofi -Aventis's Saredutant, Pfi zer's Lyrica, Pfi zer's PD-332334, Takeda/Lundbeck's Lu AA21004, Synosia Therapeutics' Rufi namide, Sepracor's SEP- 225441 and AstraZeneca's AZD-7325.
• GAD market: 2007 statistics, outlook for emerging agents.